Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

38.33 -0.47 (-1.22%)
Streaming Delayed Price Updated: 11:27 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Where Xenon Pharmaceuticals Stands With Analysts
Via Benzinga
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Xenon Pharmaceuticals Earnings Preview
Via Benzinga
The Latest Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, April 25, 2023: GM, SNAP, WEN, XENE, CXAI
General Motors (GM) - Shares traded about 3% higher Tuesday morning following better-than-expected Q1 earnings and sales and raised guidance. The company said global deliveries of its automobiles 
Via Benzinga
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Where Xenon Pharmaceuticals Stands With Analysts
Via Benzinga
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company
A recent merger between Applied UV Inc. (NASDAQ: AUVI), Puro Lighting (PURO), and LED Supply Co. (LED Supply) seems to have triggered some excitement in the ultraviolet (UV) disinfection equipment... 
Via Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
Via Benzinga
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.